Manejo farmacológico de la atrofia vaginal en mujeres posmenopáusicas en atención primaria de la salud

Abstract

INTRODUCTION: Vulvo-vaginal atrophy is a condition that occurs because of histological and functional alterations that begin in menopause, causing annoying symptoms that affect the quality of life of postmenopausal women. OBJECTIVE: To determine the pharmacological management of vulvar-vaginal atrophy in postmenopausal primary health care METHODOLOGY: We conducted searches in academic and scientific databases, such as PubMed, Google Académico and Scielo and selected articles published in indexed journals during the period from 2018 to 2023, that specifically address the hormonal management of vulvo-vaginal atrophy in postmenopausal women. DEVELOPMENT: A study in 57 postmenopausal women found that estriol lubricant had better results in vaginal health (p=0.018), with a 72% symptomatology reduction vs 87%. In the study conducted in Colombia, where estriol, polyresulene and vaginal lubricant were compared, it was observed that the improvement of vaginal health symptoms with the use of estriol was 92%, as well as a better score in the index of Female Sexual Function Abbreviated-6, (estriol: 29.29 6.23; polyresolene: 28.66 6.12; and vaginal lubricant: 25.38 6.27, p = 0.021]. CONCLUSION: Hormone therapies with better results include: 10mcg estradiol intravaginal eggs, 0.5-2g estradiol cream conjugate, 4-10 mcg estradiol intravaginal tablet or capsule regimens, and 7.5mcg/day rings of estradiol and prasterone.